Product Code: 5413
Allergic Rhinitis Drugs Market is expected to grow significantly during 2023-2032, owing to the increasing rate of respiratory diseases. Air pollution is one of the critical factors contributing to the spread of respiratory infections. According to reports, asthma and chronic obstructive pulmonary disease (COPD) account for most respiratory illnesses in India.
Besides, rising air pollution leads to high levels of allergic pollen and result in a rising number of patients suffering from allergic rhinitis. The constant innovations in monitoring the impact of pollution levels on allergic rhinitis will play a key role in market expansion.
Overall, the allergic rhinitis drugs market is segmented in terms of disease, treatment, drug, route of administration, distribution channel, and region.
Considering the disease, the occupational allergic rhinitis market held over USD 1.2 billion market share in 2022 and is slated to grow exponentially through 2032. The growth can be attributed to the rising cases of occupational allergic rhinitis caused by allergens from hair spray and fumes, strong odors, diesel exhaust, pollutants from factories, and cleaning solutions. Besides, the mounting use of air conditioning and strict regulations imposed by the government regarding factory emissions will support the segmental growth by 2032.
Based on treatment, the corticosteroids segment held over USD 3.6 billion market share in 2022 and is anticipated to register notable gains through 2032. Some key benefits offered by corticosteroids, such as near-instant pain relief, rapid reduction in inflammation, permanent cure, sometimes, in the case of a localized injury, and a high success rate, are expected to propel the product adoption.
On the basis of drug, the OTC segment is depicted to grow considerably through 2032, owing to the availability of several medications for allergic rhinitis treatment on non-prescription or over the counter. The rising trend of self-medication, coupled with the increasing adoption of online platforms for ordering medicines, will play a key role in complementing the segmental expansion.
By route of administration, the nasal segment accounted for over USD 4.6 billion in 2022 and is slated to grow exponentially over the forecast period, owing to the increasing use of nasal sprays as one of the primary medications for treating allergic rhinitis. Besides, nasal sprays relieve inflammation faster, are easy to use, and available as over-the-counter products. All these factors are anticipated to accelerate the product development.
Considering the distribution channel, the retail pharmacy segment held over 33% market share in 2022 and is slated to register healthy growth during the estimated timeframe. Easy accessibility and availability of different medications at affordable price ranges are key factors supporting the segment expansion in the coming years.
Regionally, the Europe allergic rhinitis drugs market accounted for over 30% revenue share in 2022 and is expected to witness significant growth throughout 2032. The rising inclination of consumers towards allergic self-medication trends and high disposable income are some of the key factors that are projected to drive the regional market growth in the ensuing years.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Industry coverage
- 1.2 Market scope & definitions
- 1.3 Base estimates & working
- 1.4 Forecast parameters
- 1.5 COVID-19 impact analysis at global level
- 1.6 Data validation
- 1.7 Data sources
- 1.7.1 Primary
- 1.7.2 Secondary
- 1.7.2.1 Paid sources
- 1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Allergic rhinitis drugs industry 360 degree synopsis, 2018 - 2032
- 2.2 Business trends
- 2.2.1 Disease type trends
- 2.2.2 Treatment type trends
- 2.2.3 Drug type trends
- 2.2.4 Route of administration trends
- 2.2.5 Distribution channel trends
- 2.2.6 Regional trends
Chapter 3 Allergic Rhinitis Drugs Industry Insights
- 3.1 Industry segmentation
- 3.2 Industry landscape, 2018 - 2032
- 3.3 Industry impact forces
- 3.3.1 Growth drivers
- 3.3.1.1 Rising awareness about the allergic reactions and available treatment modes
- 3.3.1.2 Increasing prevalence of allergic rhinitis
- 3.3.1.3 Technological advancements in the field of allergy diagnosis and treatment
- 3.3.1.4 Growing pollution levels coupled with rise in respiratory disorders
- 3.3.2 Industry pitfalls & challenges
- 3.3.2.1 Side effects associated allergic rhinitis treatments
- 3.3.2.2 Similarity of symptoms with other diseases
- 3.4 Growth potential analysis
- 3.4.1 By disease type
- 3.4.2 By treatment type
- 3.4.3 By drug type
- 3.4.4 By route of administration
- 3.4.5 By distribution channel
- 3.5 COVID-19 impact analysis
- 3.6 Technology landscape
- 3.7 Drug approval scenario
- 3.8 Allergic Rhinitis: Causes and treatment scenario
- 3.9 Product pipeline analysis
- 3.10 List of drugs used in allergic rhinitis medication
- 3.11 Key market trends
- 3.12 Epidemiology scenario
- 3.13 Regulatory landscape
- 3.13.1 U.S.
- 3.13.2 Europe
- 3.14 Gap analysis
- 3.15 Reimbursement scenario
- 3.16 Porter's analysis
- 3.16.1 Industry rivalry
- 3.16.2 Bargaining power of suppliers
- 3.16.3 Bargaining power of buyers
- 3.16.4 Threat of substitute
- 3.16.5 Threat of new entrants
- 3.17 PESTEL analysis
- 3.17.1 Political
- 3.17.2 Economical
- 3.17.3 Social
- 3.17.4 Technological
- 3.17.5 Legal
- 3.17.6 Environmental
Chapter 4 Competitive Landscape, 2021
- 4.1 Introduction
- 4.2 Company matrix analysis, 2021
- 4.3 Strategy dashboard, 2021
Chapter 5 Allergic Rhinitis Drugs Market, By Disease Type
- 5.1 Key segment trends
- 5.2 Seasonal allergic rhinitis
- 5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.3 Perennial allergic rhinitis
- 5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 5.4 Occupational allergic rhinitis
- 5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Allergic Rhinitis Drugs Market, By Treatment Type
- 6.1 Key segment trends
- 6.2 Antihistamines
- 6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.3 Immunotherapy
- 6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.3.2 SCIT
- 6.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.3.3 SLIT
- 6.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.4 Corticosteroids
- 6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.5 Decongestants
- 6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.6 Others
- 6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Allergic Rhinitis Drugs Market, By Drug Type
- 7.1 Key segment trends
- 7.2 Prescription
- 7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 7.3 OTC
- 7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Allergic Rhinitis Drugs Market, By Route of Administration
- 8.1 Key segment trends
- 8.2 Oral
- 8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 8.3 Nasal
- 8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 8.4 Intraocular
- 8.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 8.5 Intravenous
- 8.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Allergic Rhinitis Drugs Market, By Distribution Channel
- 9.1 Key segment trends
- 9.2 Retail pharmacies
- 9.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 9.3 Hospital pharmacies
- 9.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 9.4 Online channel
- 9.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 10 Allergic Rhinitis Drugs Market, By Region
- 10.1 Key regional trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.6 Middle East & Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
Chapter 11 Company Profiles
- 11.1 Merck & Co.
- 11.2 Teva Pharmaceutical Industries Ltd.
- 11.3 GlaxoSmithKline PLC
- 11.4 Boehringer Ingelheim
- 11.5 Stallergenes Greer
- 11.6 Unichem Laboratories
- 11.7 Sanofi S.A.
- 11.8 Johnson & Johnson
- 11.9 Alcon (Novartis AG)
- 11.10 Mylan NV
- 11.11 Meda AB
- 11.12 Allergy Therapeutics PLC
- 11.13 Glenmark Pharmaceuticals Ltd
- 11.14 ALK-Abello A/S
- 11.15 Bayer AG
- 11.16 Adamis Pharmaceuticals
- 11.17 Dr Reddy's Laboratories
- 11.18 Sun Pharmaceuticals